Literature DB >> 22699215

[Renal emergencies in cases of collagenosis and vasculitis].

M Janneck1, C Iking-Konert.   

Abstract

Renal involvement or complications in systemic diseases occur frequently and crucially influence patient outcomes. In addition to functional renal failure caused by medications (especially nonsteroidal antirheumatic agents), typical nephrological complications in rheumatology include manifestations of the underlying condition which range from mild disorders of renal function to severe and partially irreversible disease progression. The primary physician thus plays a key role in ensuring rapid and specific diagnostic workup and initiating appropriate treatment measures. Sonography and examination of urine sediment still take priority in the differential diagnosis. The indication for kidney biopsy should be broadly defined. Early initiation of immunosuppression in systemic diseases can decisively improve renal prognosis. Despite the current availability of considerably improved pharmacological options, numerous questions about the ideal therapeutic regimen still remain open.

Entities:  

Mesh:

Year:  2012        PMID: 22699215     DOI: 10.1007/s00393-011-0915-2

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  26 in total

Review 1.  Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.

Authors:  M Aringer; H Burkhardt; G R Burmester; R Fischer-Betz; M Fleck; W Graninger; F Hiepe; A M Jacobi; I Kötter; H J Lakomek; H M Lorenz; B Manger; G Schett; R E Schmidt; M Schneider; H Schulze-Koops; J S Smolen; C Specker; T Stoll; A Strangfeld; H P Tony; P M Villiger; R Voll; T Witte; T Dörner
Journal:  Lupus       Date:  2011-11-09       Impact factor: 2.911

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

4.  EULAR recommendations for the management of primary small and medium vessel vasculitis.

Authors:  C Mukhtyar; L Guillevin; M C Cid; B Dasgupta; K de Groot; W Gross; T Hauser; B Hellmich; D Jayne; C G M Kallenberg; P A Merkel; H Raspe; C Salvarani; D G I Scott; C Stegeman; R Watts; K Westman; J Witter; H Yazici; R Luqmani
Journal:  Ann Rheum Dis       Date:  2008-04-15       Impact factor: 19.103

Review 5.  [Is methotrexate nephrotoxic? Dose-dependency, comorbidities and comedication].

Authors:  U Erdbrügger; K de Groot
Journal:  Z Rheumatol       Date:  2011-09       Impact factor: 1.372

Review 6.  Therapeutic plasma exchange in renal diseases.

Authors:  F Madore; J M Lazarus; H R Brady
Journal:  J Am Soc Nephrol       Date:  1996-03       Impact factor: 10.121

Review 7.  Scleroderma renal crisis: a rare but severe complication of systemic sclerosis.

Authors:  Luc Mouthon; Alice Bérezné; Guillaume Bussone; Laure-Hélène Noël; Peter M Villiger; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

8.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

Authors:  O Kowal-Bielecka; R Landewé; J Avouac; S Chwiesko; I Miniati; L Czirjak; P Clements; C Denton; D Farge; K Fligelstone; I Földvari; D E Furst; U Müller-Ladner; J Seibold; R M Silver; K Takehara; B Garay Toth; A Tyndall; G Valentini; F van den Hoogen; F Wigley; F Zulian; Marco Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2009-01-15       Impact factor: 19.103

9.  Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis.

Authors:  E González; E Gutiérrez; C Galeano; C Chevia; P de Sequera; C Bernis; E G Parra; R Delgado; M Sanz; M Ortiz; M Goicoechea; C Quereda; T Olea; H Bouarich; Y Hernández; B Segovia; M Praga
Journal:  Kidney Int       Date:  2008-01-09       Impact factor: 10.612

10.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.

Authors:  Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.